Sara Kashani1, Tara F Carr2, Leslie C Grammer3, Robert P Schleimer4, Kathryn E Hulse3, Atsushi Kato3, Robert C Kern5, David B Conley5, Rakesh K Chandra5, Bruce K Tan5, Anju T Peters6. 1. Feinberg School of Medicine, Northwestern University, Chicago, Ill. 2. Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, College of Medicine, The University of Arizona, Tucson, Ariz. 3. Division of Allergy-Immunology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill. 4. Division of Allergy-Immunology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill; Department of Otolaryngology-Head and Neck Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Ill. 5. Department of Otolaryngology-Head and Neck Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Ill. 6. Division of Allergy-Immunology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill. Electronic address: anjupeters@northwestern.edu.
Abstract
BACKGROUND: Specific antibody deficiency (SAD) involves a deficient response to a polysaccharide vaccine in the setting of normal immunoglobulin G (IgG) levels and chronic infections. Patients with chronic rhinosinusitis (CRS) are often evaluated for SAD. There are limited data that describe patients with CRS and SAD. OBJECTIVE: The objective of this study was to better characterize the role of SAD in CRS. METHODS: We reviewed electronic records of adults with CRS who were evaluated for immunodeficiency with quantitative Ig levels and pre- and postantibody titers to a pneumococcal polysaccharide vaccine (PPV). RESULTS: Fourteen pneumococcal serotypes were determined in 239 subjects from 2002 to 2009. Of these subjects, 64 had adequate protective titers of 1.3 μg/mL or higher in 7 or more serotypes of the 14 serotypes checked; 56 (23%) had less than 7 protective titers post-PPV and were diagnosed with SAD; and 119 had an adequate response to the vaccine with 7 or more serotypes being higher than 1.3 μg/mL (>50% response) and were characterized as "responders." Subjects with SAD received more antibiotic courses relative to responders in the 2 years after immunization (3.19 ± 2.64 vs 2.19 ± 2.24, P < .05). Of 56 subjects with SAD, 10 (17.9%) received Ig replacement therapy. Subjects who received Ig had fewer numbers of protective pneumococcal titers post-PPV and had more pneumonia (40.0%) versus subjects with SAD who did not receive Ig (10.9%). CONCLUSIONS: Of the 239 patients with CRS with normal IgG levels evaluated for immunodeficiency, 56 (23.4%) had SAD. A majority of patients with SAD may not need Ig replacement; however, a subset of patients with SAD benefit from Ig replacement.
BACKGROUND: Specific antibody deficiency (SAD) involves a deficient response to a polysaccharide vaccine in the setting of normal immunoglobulin G (IgG) levels and chronic infections. Patients with chronic rhinosinusitis (CRS) are often evaluated for SAD. There are limited data that describe patients with CRS and SAD. OBJECTIVE: The objective of this study was to better characterize the role of SAD in CRS. METHODS: We reviewed electronic records of adults with CRS who were evaluated for immunodeficiency with quantitative Ig levels and pre- and postantibody titers to a pneumococcal polysaccharide vaccine (PPV). RESULTS: Fourteen pneumococcal serotypes were determined in 239 subjects from 2002 to 2009. Of these subjects, 64 had adequate protective titers of 1.3 μg/mL or higher in 7 or more serotypes of the 14 serotypes checked; 56 (23%) had less than 7 protective titers post-PPV and were diagnosed with SAD; and 119 had an adequate response to the vaccine with 7 or more serotypes being higher than 1.3 μg/mL (>50% response) and were characterized as "responders." Subjects with SAD received more antibiotic courses relative to responders in the 2 years after immunization (3.19 ± 2.64 vs 2.19 ± 2.24, P < .05). Of 56 subjects with SAD, 10 (17.9%) received Ig replacement therapy. Subjects who received Ig had fewer numbers of protective pneumococcal titers post-PPV and had more pneumonia (40.0%) versus subjects with SAD who did not receive Ig (10.9%). CONCLUSIONS: Of the 239 patients with CRS with normal IgG levels evaluated for immunodeficiency, 56 (23.4%) had SAD. A majority of patients with SAD may not need Ig replacement; however, a subset of patients with SAD benefit from Ig replacement.
Authors: Francisco A Bonilla; I Leonard Bernstein; David A Khan; Zuhair K Ballas; Javier Chinen; Michael M Frank; Lisa J Kobrynski; Arnold I Levinson; Bruce Mazer; Robert P Nelson; Jordan S Orange; John M Routes; William T Shearer; Ricardo U Sorensen Journal: Ann Allergy Asthma Immunol Date: 2005-05 Impact factor: 6.347
Authors: Raymond G Slavin; Sheldon L Spector; I Leonard Bernstein; Michael A Kaliner; David W Kennedy; Frank S Virant; Ellen R Wald; David A Khan; Joann Blessing-Moore; David M Lang; Richard A Nicklas; John J Oppenheimer; Jay M Portnoy; Diane E Schuller; Stephen A Tilles; Larry Borish; Robert A Nathan; Brian A Smart; Mark L Vandewalker Journal: J Allergy Clin Immunol Date: 2005-12 Impact factor: 10.793
Authors: Thomas R Talbot; Tina V Hartert; Ed Mitchel; Natasha B Halasa; Patrick G Arbogast; Katherine A Poehling; William Schaffner; Allen S Craig; Marie R Griffin Journal: N Engl J Med Date: 2005-05-19 Impact factor: 91.245
Authors: Young J Juhn; Hirohito Kita; Barbara P Yawn; Thomas G Boyce; Kwang H Yoo; Michaela E McGree; Amy L Weaver; Peter Wollan; Robert M Jacobson Journal: J Allergy Clin Immunol Date: 2008-09-13 Impact factor: 10.793
Authors: Anjeni Keswani; Neha M Dunn; Angelica Manzur; Sara Kashani; Xavier Bossuyt; Leslie C Grammer; David B Conley; Bruce K Tan; Robert C Kern; Robert P Schleimer; Anju T Peters Journal: J Allergy Clin Immunol Pract Date: 2017-01-26
Authors: L Klimek; A Chaker; C Matthias; A Sperl; P Gevaert; P Hellings; B Wollenberg; M Koennecke; J Hagemann; J Eckrich; S Becker Journal: HNO Date: 2019-09 Impact factor: 1.284